Loading company
Cocrystal Pharma, Inc.
COCP · Nasdaq · ·
$1.13-7.0%Sep 29 close
- 1M
- +2.7%
- 6M
- +13.0%
- 1Y
- -9.6%
- 5Y
- -91.1%
COCP · Nasdaq · ·
$1.13-7.0%Sep 29 close
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2020 | Change |
|---|---|---|---|
| Total Revenue | $105K | $554K | -81.05% |
| Profit | -$3.2M | -$2.1M | -53.97% |
| Profit per share | -$0.23 | -$0.20 | -15.00% |
| Free Cash Flow | -$1.7M | -$4.5M | +61.52% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Cocrystal Pharma, Inc. has no earnings call transcript available.
“We are delighted to report that our norovirus human challenge study evaluating efficacy and safety of CDI-988 is underway at Emory University School of Medicine. In our first cohort, healthy subjects are being inoculated with the GII.2 (Snow Mountain Virus) strain under highly controlled conditions,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of noroviruses, influenza viruses, coronaviruses (including SARS-CoV-2) and hepatitis C viruses. Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create viable antiviral drugs.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Cocrystal Pharma, Inc.’s Item 2.02 8-K filed March 31, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.